triazoles has been researched along with Primary Myelofibrosis in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Anderson, A; Camargo, JF; Komanduri, KV; Lekakis, L; Martinez, OV; Mendoza, MA; Morris, MI; Prado, CE; Simkins, J | 1 |
Bazargan, A; Chai, KL; Kostos, L; Tam, CS | 1 |
Ihling, C; Tesch, H | 1 |
Giagounidis, A; Groepper, S; Haferlach, C; Schlue, J | 1 |
Bateman, AC; Clarridge, J; Garvin, K; Greenbaum, A; Grim, J; Liu, AW | 1 |
Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G | 1 |
Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G | 1 |
Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
8 other study(ies) available for triazoles and Primary Myelofibrosis
Article | Year |
---|---|
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Azoles; Drug Resistance, Fungal; Female; Hematopoietic Stem Cell Transplantation; Humans; Invasive Fungal Infections; Microbial Sensitivity Tests; Middle Aged; Nitriles; Primary Myelofibrosis; Pyridines; Triazoles | 2020 |
The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
Topics: Aged; Benzoates; Bone Marrow; Deferasirox; Erythropoiesis; Female; Humans; Image-Guided Biopsy; Immunohistochemistry; Iron Chelating Agents; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Positron-Emission Tomography; Primary Myelofibrosis; Triazoles | 2017 |
Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Primary Myelofibrosis; Spherocytosis, Hereditary; Treatment Outcome; Triazoles | 2013 |
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.
Topics: Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Iron Chelating Agents; Primary Myelofibrosis; Remission Induction; Treatment Outcome; Triazoles | 2016 |
Cutaneous phaeohyphomycosis in a hematopoietic stem cell transplant patient caused by Alternaria rosae: First case report.
Topics: Acute Kidney Injury; Acyclovir; Aged; Alternaria; Alternariosis; Antibiotic Prophylaxis; Antifungal Agents; Drug Therapy, Combination; Fatal Outcome; Graft vs Host Disease; Hand; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Levofloxacin; Magnetic Resonance Imaging; Male; Microbial Sensitivity Tests; Paranasal Sinuses; Phaeohyphomycosis; Pneumonia; Prednisone; Primary Myelofibrosis; Respiratory Insufficiency; Spores, Fungal; Transplantation, Homologous; Triazoles; Voriconazole | 2017 |
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2008 |
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2009 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |